| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1642 |
| Trial ID | NCT02892695 |
| Disease | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Mantle Cell Lymphoma | B-Cell Prolymphocytic Leukemia | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | CD19 CAR-NK cells |
| Generation | 3rd |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma |
| Year | 2016 |
| Country | China |
| Company sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Other ID(s) | PG-119-001 |
| Cohort 1 | |||||||||||
|
|||||||||||